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Abstract
Antibodies constitute a critical component of the naturally acquired immunity that develops following frequent exposure to
malaria. However, specific antibody titres have been reported to decline rapidly in the absence of reinfection, supporting
the widely perceived notion that malaria infections fail to induce durable immunological memory responses. Currently,
direct evidence for the presence or absence of immune memory to malaria is limited. In this study, we analysed the
longevity of both antibody and B cell memory responses to malaria antigens among individuals who were living in an area
of extremely low malaria transmission in northern Thailand, and who were known either to be malaria naı¨ve or to have had
a documented clinical attack of P. falciparum and/or P. vivax in the past 6 years. We found that exposure to malaria results in
the generation of relatively avid antigen-specific antibodies and the establishment of populations of antigen-specific
memory B cells in a significant proportion of malaria-exposed individuals. Both antibody and memory B cell responses to
malaria antigens were stably maintained over time in the absence of reinfection. In a number of cases where antigen-
specific antibodies were not detected in plasma, stable frequencies of antigen-specific memory B cells were nonetheless
observed, suggesting that circulating memory B cells may be maintained independently of long-lived plasma cells. We
conclude that infrequent malaria infections are capable of inducing long-lived antibody and memory B cell responses.
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Introduction
Malaria, a parasitic disease of humans caused predominantly by
two species of Plasmodium, P. falciparum and P. vivax, remains an
important cause of mortality and morbidity in many parts of the
world. Development of a vaccine against malaria has proven
challenging due to the complex nature of the parasite and to the
difficulty in correlating naturally-acquired immune responses with
clinical immunity. While immunity against some of the severe
clinical symptoms may be achieved quite rapidly, following
perhaps as few as one or two infections [1], immune effector
mechanisms capable of controlling parasite growth develop only
after repeated infections over a number of years. Even with
repeated infections, protective immunity to malaria is not
complete, and asymptomatic infections may exist throughout life.
Understanding the causes of this continuing susceptibility to
infection and, in particular, understanding the development and
maintenance of immunological memory, is essential for rational
development of malaria vaccines.
Antibodies are a crucial component of naturally acquired
protective immunity against blood stage malaria with roles that
may include inhibition of merozoite invasion into new red blood
cells (RBCs), blocking cytoadherence of infected RBCs (iRBCs) to
endothelial cells, and enhancing phagocytic activity of monocytes
and macrophages (reviewed in [2,3]). It is widely believed that
periodic reinfection is required to maintain acquired immunity to
malaria and that antimalarial antibodies are short-lived in the
absence of reinfection (reviewed in [4]); implying that B cell
memory to malaria may be defective or suboptimal. However, the
development and persistence of B cell memory following malaria
infection has long been a matter of debate (reviewed in [5]). Some
studies in animal models have shown that memory B cells do
develop and are maintained normally after malaria infection [6,7];
whereas others have found that malaria infection interferes with
the development of memory B cells and long-lived plasma cells
[8,9]. In humans, several studies have demonstrated stable
antibody responses to malaria antigens [10,11,12], however,
short-lived antibody responses have also been observed [13,14],
especially in young children [10,15]. To date, very few studies
have examined the induction and maintenance of malaria-specific
memory B cells in humans. Dorfman et al [14] were frequently
unable to detect circulating malaria-specific B cells in antibody
seropositive children, but it is unclear whether this reflects an
absence of such cells or a lack of sensitivity in the assays used to
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detect them. Conversely, Asito et al [16] observed an increase in
both the total CD38+IgD2 memory B cell population and the
transitional CD10+CD19+ B cell population, following an episode
of acute malaria in African children but this study lacked any
analysis of the specificity of B cell responses as well as any long
term follow up to ascertain the duration of the response.
The aim of this study was to investigate the longevity of the
human B cell memory response to malaria in individuals with one
or more known malaria infections. To do this, we identified
individuals living in an area of very low malaria endemicity in
Northern Thailand who were either malaria naı¨ve or who had had
recorded (and parasitologically confirmed) clinical episodes of P.
falciparum or P vivax infection some years previously and
characterised the antibody and memory B cell response to a
variety of discrete P. falciparum and P. vivax antigens under
conditions of infrequent re-exposure/boosting of the immune
response.
Results
Characteristics of the study subjects at recruitment
Malaria-specific humoral immune responses of 93, HIV
negative Thai adults were studied (Table 1). Individuals were
assigned to one of three groups according to their place of
residence and their prior malaria history. Subjects from Chiang
Mai were designated ‘‘City Naı¨ve’’ (n = 17). Subjects from Muang
Na (Chiang Dao) were designated ‘‘Rural with no clinical malaria
episode (Rural 1; n = 30)’’ if they reported no prior episodes of
malaria infection and/or if no record of malaria infection was
found in the past 6 years.
Muang Na residents who had had one or more fully
documented episodes of infection with P. falciparum, P. vivax or
both parasite species, as well as those who recalled a previous
infection and were seropositive to P. falciparum schizont extract
(PfSE) but for whom hospital records could not be found, were
designated as ‘‘previously malaria infected’’ (Rural 2; n= 46). In
this group, 21 subjects (45.7%) reported at least one episode of
infection with P. falciparum, 14 (30.4%) reported at least one
episode of infection with P. vivax and 6 (13.0%) reported infection
with both species in the past 6 years. The frequency of malaria
infections within the six years prior to recruitment varied from 1–3
episodes (mean 1.2560.56 episodes for P. falciparum and
1.1060.26 for P. vivax). Five Rural 2 subjects (10.9%) were
strongly seropositive to PfSE and recalled prior malaria episodes,
but no documentary evidence of these malaria episodes was found.
The time since last documented malaria infections prior to
recruitment varied from 4–58 (21.2612.9) months for those
known to have been infected with P. falciparum and 7–39
(20.6610.1) months for those known to have been infected with
P. vivax.
Of the 76 rural subjects included at enrolment, 49 (64.5%) were
seen again at 3 months, 44 (57.9%) at 6 months and 51 (67.1%) at
12 months. All city individuals were re-sampled 3 months later.
None of the subjects were infected with P. falciparum or P. vivax -
as determined by blood film examination and PCR - at any visit.
However, one of 76 rural subjects demonstrated a significant
increase in antibody titre during the study (but only to one antigen,
PfSE) suggesting that this individual may have experienced a
Table 1. Characteristics of study subjects at recruitment.
City Rural 1 Rural 2
Total (at recruitment) - no. 17 31 46
Sex - no. (%)
Male 8 (47.1) 11 (35.5) 25 (54.3)
Female 9 (53.9) 20 (64.5) 21 (46.7)
Age - yr.
Mean 6 SD 34.768.1 32.668.5 33.767.3
Range 23–46 19–46 19–48
Recorded malaria episodes[a] - no. (%)
P. falciparum only 21 (45.7)
P. vivax only 14 (30.4)
Both P. falciparum and P. vivax 6 (13.0)
Unknown 5 (10.9)
Frequency of recorded malaria episodes[a,b] - no.
Mean P. falciparum 6 SD 1.2560.56
Range P. falciparum 1–3
Mean P. vivax 6 SD 1.1060.26
Range P. vivax 1–2
Time since last malaria episode[b] - mo.
Mean P. falciparum 6 SD 21.2612.9
Range P. falciparum 4–58
Mean P. vivax 6 SD 20.6610.1
Range P. vivax 7–39
[a]Malaria episodes that were within 45 days apart were considered as a single
episode.
[b]Malaria episodes based on records from the Office of Vector Borne Disease
Control, Department of Communicable Diseases Control, the Ministry of
Public Health, Thailand.
doi:10.1371/journal.ppat.1000770.t001
Author Summary
It is widely perceived that immunity to malaria is short-
lived, rendering people susceptible to repeated malaria
infections. However, there have been very few studies on
‘‘memory’’ responses, how the human immune system
recognizes previously encountered malaria parasites. In
particular, very little is known about the durability of
malaria-specific B cells and antibodies. The aim of this
study was to investigate the induction and maintenance of
B cell memory responses to malaria parasites in a region of
Thailand where people become infected with malaria, but
where the levels of malaria transmission are so low that
repeated infection is uncommon. From hospital records
we were able to identify people who either had been
infected with malaria over the past 6 years and/or had
never been infected. Blood samples were collected on four
separate occasions over a period of one year and analysed
by microscopy and PCR for presence of malaria parasites
and by ELISA and ELISPOT for anti malarial antibodies and
malaria-specific memory B cells. We found that, in a
significant proportion of individuals, malaria infection
results in the generation of antibodies and the establish-
ment of populations of memory B cells against malaria
parasites, which were very stably maintained over time
despite the lack of any evidence of malaria reinfection.
Contrary to the widely held idea that memory to malaria is
suboptimally induced, our data demonstrate that B cell
responses to malaria can be maintained for many years
after a malaria infection and indicate that there is no
inherent reason why malaria vaccines should not also
induce long-lasting protection against malaria.
B Cell Memory Responses to Plasmodium
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recent malaria infection, even though they did not report being ill.
The three groups did not differ significantly by age or sex.
Antibody levels against tetanus toxoid (TT) were measured by
indirect ELISA. There was no significant difference among the
groups in the overall levels of antibodies to TT (Fig. 1A) but only
23.7% of the rural subjects (Rural 1 + Rural 2, n = 76) were
seropositive for TT at the time of recruitment. Among the rural
individuals (Rural 1 + Rural 2) who had blood collected at
recruitment and 12 months later (n = 51), the seropositivity rate
for TT (19.6%) did not differ between the two time points
(Fig. 1G). The individual data for the rural subjects who were
seropositive for TT at the time of recruitment and had blood
collected more than one time point (n = 17) are shown in
Figure 1M.
Antibody responses to PfSE
Relative antibody titres to PfSE were measured, at the time of
enrolment and at subsequent follow-up. Among the Rural 1
population, 4 (13.3%) individuals had antibody responses above
the cut-off, indicating that they had, in fact, been exposed to
malaria (Fig. 1B). Among Rural 2 subjects, 25 (54.4%) individuals
were seropositive for PfSE. The proportion of seropositives in the
Rural 2 group was significantly higher than in the Rural 1 group
(p = 0.0003; Fisher’s exact test).
There was no difference in the levels of anti-PfSE antibodies
between subjects who had been infected with P. falciparum only or
infected with P. vivax only (Fig. S1). Overall, the Rural 2 group had
levels of anti-PfSE antibodies that were significantly higher than
the Rural 1 group (p = 0.0005; Mann Whitney U test). There was
no correlation between the levels of anti-PfSE antibodies and age
of the subjects or the number of previous malaria episodes they
had experienced (data not shown).
Among the rural subjects (Rural 1 + Rural 2) who had blood
collected at the beginning and at the end of the study (n = 51), 19
(37.3%) were seropositive for PfSE at the time of recruitment and
all of these remained positive 12 months later (Fig. 1H). The
individual data for the rural subjects who were seropositive at the
time of recruitment and had blood collected at more than one time
point (n = 25) are shown in Figure 1N.
Antibody responses to defined P. falciparum antigens
Antibody responses to recombinant malaria antigens PfAMA-1,
PfMSP-119, PfMSP-2 and PfCSP were examined by indirect
ELISA. PfAMA-1, PfMSP-119 and PfMSP-2 are antigens of blood
stage merozoites. PfCSP is the major surface protein on the surface
of sporozoites, the infective stage of the malaria parasite. All of
these antigens are key P. falciparum vaccine candidates. City naive
subjects were seronegative to all P. falciparum antigens tested
(Fig. 1C–1F). Among the thirty rural individuals with no known
episodes of malaria infection in the past 6 years (Rural 1), 7 (23%),
4 (13%), 1 (3%) and 3 (10%) subjects had positive antibody titres
against PfAMA-1, PfMSP-119, PfMSP-2 and PfCSP, respectively
(Fig. 1C–1F). Seropositivity to individual malaria antigens, and to
PfSE, was not significantly correlated (data not shown) and,
overall, 10 (33%) Rural 1 subjects were seropositive to one or more
P. falciparum antigens.
The frequencies of antibody responses to PfAMA-1, PfMSP-119,
PfMSP-2 and PfCSP in the previously infected (Rural 2) group
were 17 (37%), 22 (48%), 7 (15%) and 4 (9%), respectively. Again,
seropositivity to individual malaria antigens was not significantly
correlated (data not shown) and, overall, 30 (65%) Rural 2 subjects
were seropositive to one or more P. falciparum antigens (schizont
extract and/or recombinant proteins). The proportion of individ-
uals in the Rural 2 and Rural 1 groups who were seropositive for
recombinant malaria antigens was not significantly different,
except that a higher proportion of Rural 2 were seropositive for
PfMSP-119 (p = 0.003; Fisher’s exact test).
The titres of antibodies to PfMSP-119 and PfMSP-2 were
significantly higher among Rural 2 subjects than among Rural 1
subjects but among the Rural 2 group the levels of antibodies to
individual P. falciparum antigens were not different between
previously P. falciparum- and P. vivax- infected subjects (data not
shown). Moreover, the titres of antibodies against P. falciparum
antigens in some Rural 2 subjects were at least as high as those of
the positive control of pooled adult African sera. There was no
detectable antibody response to the carrier proteins used in the
production of recombinant antigens (data not shown).
Several subjects reporting prior infection only with P. vivax had
antibodies to P. falciparum antigens. Of the 14 individuals with
recorded P. vivax infections but no recorded P. falciparum infections,
8 (57%) had antibodies to at least one P. falciparum antigen. This is
consistent with results of previous studies [17,18,19] and may
reflect an undiagnosed prior infection with P. falciparum or cross-
reactivity of antibodies to the two parasite species [17,20,21,22].
As shown in Fig. 1I–1L, most of the subjects who were
seropositive at recruitment and who were tested again 12 months
later remained seropositive. The individual data for the rural
subjects who were seropositive for the different malaria antigens at
the time of recruitment and had blood collected at more than one
time point are shown in Fig. 1O–1R. At an individual level, titres
of antibodies against PfAMA-1, PfMSP-119 and PfMSP-2 were
significantly correlated with titres of anti-PfSE Abs (data not
shown). No correlations between age and the antibody titres
against individual malaria antigens were found (data not shown).
Antibody responses to P. vivax antigens
We also investigated the antibody responses to P. vivax antigens,
PvAMA-1, PvMSP119 and PvDBP by ELISA, all of which are P.
vivax blood stage antigens and are key vaccine candidates. City
naı¨ve subjects were seronegative to all P. vivax antigens (Fig. 2A–
2C). Among Rural 1 subjects, none were seropositive to PvAMA-1
(Fig. 2A), one (3%) had a borderline positive titre to PvMSP-119
(Fig. 2B) and two (6.7%) were seropositive to PvDBP (Fig. 2C). Of
the Rural 2 subjects, 5 (11%), 5 (11%) and 3 (6.5%) were
seropositive to PvAMA-1, PvMSP-119 and PvDBP, respectively.
Overall, 8 (17.4%) Rural 2 subjects were seropositive to one or
more P. vivax recombinant antigens. Of the 20 subjects known to
have been previously infected with P. vivax (P. vivax only or both P.
vivax and P. falciparum), 5 (25%) were seropositive to one or more P.
vivax antigens and 15 (75%) were seronegative. The proportion of
subjects who were seropositive to P. vivax antigens did not differ
significantly between the Rural 1 and Rural 2 groups. Similarly,
no significant differences in anti-P. vivax antibody titres were
observed between the Rural 1 and Rural 2 groups, although the
power of this analysis was poor due to the very low numbers of
seropositive subjects. Antibody responses to P. vivax antigens were
not different between subjects known to have been infected with P.
falciparum- and those known to have been infected with P. vivax
(data not shown). Most of the subjects who were seropositive to P.
vivax antigens at the time of recruitment and who had samples
collected at more than one time point remained seropositive over
the course of the study and there was no evidence of declining
titres (Fig. 2D–2F).
Avidity of antibodies to PfAMA-1 and PfMSP-119
Antibody avidity tends to increase over time as a result of
somatic mutation in the immunoglobulin-encoding genes of
germinal centre B cells and in response to increasing competition
B Cell Memory Responses to Plasmodium
PLoS Pathogens | www.plospathogens.org 3 February 2010 | Volume 6 | Issue 2 | e1000770
Figure 1. Antibody responses to P. falciparum antigens and tetanus toxoid. Antibody titres against tetanus toxoid (A) and P. falciparum
antigens (B–F) among City naı¨ve (circle), Rural 1 (triangle) or Rural 2 (inverted triangle) subjects at the time of recruitment were determined by indirect
ELISA. Each symbol represents the antibody titre of one individual. Solid lines show the median antibody titres in each group. The Mann Whitney U
test was used to analyse differences in the levels of antibodies or memory B cells among groups. Figures G–L show the percentages of all rural (i.e.
Rural 1 plus Rural 2) subjects who had antibody titres above the cut-off for each antigen at the time of recruitment and 12 months later. Fischer’s
exact test was used to analyse differences in the proportion of seropositives at recruitment compared to 12 months later but no significant
differences were observed. The antibody titres for each seropositive subject over the 12 months of the study are shown in figures M–R. Dotted lines
show cut-off values calculated from a mixture model as described in materials and methods.
doi:10.1371/journal.ppat.1000770.g001
B Cell Memory Responses to Plasmodium
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between B cell clones for diminishing amounts of antigen [23,24].
To determine whether the avidity of the anti-malarial antibody
response changed over time, or whether antibody avidity was
associated with durability of antibody responses, the avidity indices
of anti-PfAMA-1 and anti-PfMSP-119 antibodies were determined
for all those individuals (as defined in Figure 1) who were
seropositive to one or other antigen at the time of recruitment.
Overall, avidity indices for antibodies to both antigens were higher
in Rural 2 group than in Rural 1 group (Fig. 3A and 3B), and this
difference was statistically significant for antibodies to PfMSP-119.
However, there was no detectable change in the avidity of
antibodies to either antigen in either group over the 12 months of
the study (Fig. 3C–3F).
Longevity of antimalarial antibodies
To determine the longevity of the antimalarial antibody
responses, we analysed the change in concentrations of antibodies
to PfSE, PfAMA-1 and PfMSP-119 in relation to time (in months)
since the last documented malaria episode (Figure 4). The half-life
of the antibody response was analysed separately for each antigen
using data from Rural 2 subjects who were seropositive at the time
of enrolment and for whom follow-up samples were obtained
(PfSE n= 14; PfAMA1 n=8; and PfMSP-119 n = 12) in a repeated
measurements analysis including multiple data points from the
same subjects. Subjects known to be infected with P. vivax but not
known to have been infected with P. falciparum were not included
in this analysis in order to ensure specificity to P. falciparum.
Mixed-effects regression models revealed very low rates of
decline (converted to years) in anti- PfSE, PfAMA-1 and PfMSP-
119 antibody concentrations over time and statistically, these rates
could not be distinguished from zero (Table 2). The best estimates
of half-lives were: 5.5 years for PfSE, 10.4 years for PfAMA-1 and
7.6 years for PfMSP-119, respectively but, in each case, the 95%
CI included infinity. Pooled regression analysis of data for
antibodies to PfAMA-1 and PfMSP-119 also yielded a rate of
decline that was not statistically significant from zero. Inclusion of
anti-PfSE antibody data in the pooled regression analysis resulted
in a marginally significant rate of decline equivalent to a half-life of
6.4 years (95% CI= 3.22, 650.48; p = 0.048). These analyses
suggest that antibody responses to malaria are stably maintained in
this population.
B cell memory responses to P. falciparum and P. vivax
antigens
We next enumerated memory B cells to malaria antigens and to
TT using a highly sensitive ELISPOT protocol [25]. The number of
subjects available for analysis was limited by availability of
cryopreserved PBMCs. Antigen-specific memory B cell frequencies
are presented as a percentage of the total number of IgG-secreting
cells. Frequencies of TT-specific memory B cells were similar among
the three study groups (Fig. 5I). No spots were detected for any
individual when cells were tested against the irrelevant control protein
(keyhole limpet hemocyanin) and no malaria-specific spots were
observed in samples from the City naı¨ve group (data not shown).
Figure 2. Antibody responses to P. vivax antigens. A–C show antibody titres against P. vivax antigens among City naı¨ve (circle), Rural 1 (triangle)
or Rural 2 (inverted triangle) subjects at the time of recruitment. Each symbol represents the antibody titre of one individual. Solid lines show the
median antibody titres in each group. The titres of antibodies of seropositive rural (i.e. Rural 1 plus Rural 2) subjects at the time of recruitment and at
each time point during the 12 months of study are shown in figures D–F. Dotted lines show cut-off values calculated from a mixture model as
described in materials and methods.
doi:10.1371/journal.ppat.1000770.g002
B Cell Memory Responses to Plasmodium
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At the time of recruitment, of the 21 Rural 1 subjects whose
PBMCs were available, 3 (14.2%), 3 (14.2%), and 1 (4.8%) subjects
had memory B cells specific to PfAMA-1 (Fig. 5A), PfMSP-119
(Fig. 5B), and PfMSP-2 (Fig. 5C), respectively. No memory B cells
specific to PfCSP were found in the Rural 1 group (Fig. 5D). A
much higher proportion of Rural 2 individuals had detectable
memory B cells: of the 33 tested, 16 (48%), 11 (33%), 6 (18%) and
1 (3%) gave spots to PfAMA-1, PfMSP-119, PfMSP-2 and PfCSP,
respectively. Overall, 19 (58%) Rural 2 subjects had memory B
cells to one or more P. falciparum recombinant antigens.
None of the 14 Rural 1 subjects tested had detectable memory B
cells against PvAMA-1, and only one individual (7%) had
detectable memory B cells to PvMSP-119 (Fig. 5E and 5F).
However, among the 26 Rural 2 individuals tested, 6 (23%) and 7
(27%) had memory B cells specific to PvAMA-1 and PvMSP-119,
respectively. Nine Rural 2 subjects (35%) had memory B cells
specific to one or more P. vivax antigens.
Stability of PfAMA-1- and PfMSP-119-specific memory B cells
For the Rural 2 individuals, we then characterised the frequency
of PfAMA-1- and PfMSP-119-specific memory B cells in relation to
time since their last documented malaria infection, using mixed-
effects regression analysis (allowing for repeated measurements
from individual subjects) as described above. We found that
PfAMA-1- and PfMSP-119 specific memory B cells were stably
maintained over time (Fig. 5G and 5H). The best estimate of the
rate of change in AMA-1-specific memory B cell numbers
indicated no decline during follow-up, whereas the best estimate
for the half-life of MSP-119-specific memory B cells was 10 years
(Table 2). Single and pooled regression analysis of data resulted in
rates of decline that, statistically, could not be distinguished from
zero. Similar observations were made for memory B cells to TT
(data not shown). These results indicate that memory B cell
responses to malaria antigens are stably maintained in this very
low transmission area.
Correlation between antibody titres and memory B cell
frequencies
It was immediately evident from the TT data that circulating
memory B cells could be detected in many (,47%) seronegative
individuals (Figure 6G). We therefore carried out a systematic
analysis of the association between circulating memory B cells and
plasma antibody titres at the individual level.
Figure 3. Avidity indices for anti-PfAMA-1 and PfMSP-119
antibodies. Avidity indices for PfAMA-1 (A) and PfMSP-119 (B) at the
time of recruitment were compared between Rural 1 and Rural 2 groups.
Avidity indices for antibodies to both antigens were compared at the
time of recruitment and at 12 months later for Rural 1 (C and D) and Rural
2 (E and F) subjects. Lines show the mean (95% CI) for each group. An
unpaired Student’s t-test test was used to analyse differences between
rural groups. A paired t-test was used to confirm that there are no
differences between indices at time of recruitment and 12 months later.
doi:10.1371/journal.ppat.1000770.g003
Figure 4. Longevity of anti-malarial antibody responses. The
titres of antibodies specific to PfSE (A), PfAMA-1 (B) and PfMSP-119 (C) in
relation to time since last clinical infection in P. falciparum exposed
individuals (Rural 2 only) were determined by analyzing longitudinal
data with a mixed-effects model. Each symbol represents the antibody
level at each time point of one individual. The regression analysis was
adjusted for inclusion of multiple data points from the same individual.
Solid lines represent best fit regression lines estimating the rates of
decline of antibody concentrations over time and the dashed lines
represent the 95% CI. Horizontal dotted lines indicate the cut-off as
defined in Materials and Methods and Figure 1.
doi:10.1371/journal.ppat.1000770.g004
B Cell Memory Responses to Plasmodium
PLoS Pathogens | www.plospathogens.org 6 February 2010 | Volume 6 | Issue 2 | e1000770
No correlation was observed between specific antibody titres
and frequencies of memory B cells (data not shown). Among the 33
Rural 2 subjects for whom we had both antibody data and
memory B cell responses to P. falciparum antigens at the time of
recruitment, 7 (21%), 8 (24%) 2 (6%) and 0 (0%) had both
circulating antibody and memory B cells to PfAMA-1, PfMSP-119,
PfMSP-2 and PfCSP respectively (Fig. 6A–6D). Four (12%), 7
(21%), 2 (6%) and 3 (9%) individuals were seropositive to the
respective antigens but no B cell spots were observed whereas 9
(27%), 3 (9%), 4 (12%), and 1 (3%) were seronegative but had
memory B cells to PfAMA-1, PfMSP-119, PfMSP-2 and PfCSP
respectively.
Of the 26 Rural 2 subjects for whom we had data on both
antibody and memory B cell responses against P. vivax antigens at
the time of recruitment, 1 (4%) and 2 (8%) individuals had both
antibody and memory B cells against PvAMA-1 and PvMSP-119
respectively (Fig. 6E and 6F), 3 (12%) and 2 (8%) gave positive
results in ELISA but not in ELISPOT, and 5 (19%) and 5 (19%)
had memory B cells but not antibodies to PvAMA-1 and PvMSP-
119, respectively. These results suggest that serum antibody levels
alone or memory B cell frequencies alone may not fully represent
the humoral immune response to malaria parasites.
Different individuals had different patterns of antibody and
memory B cell responses to the various malaria antigens. Table 3
shows the heterogeneity of such responses in all Rural 2 subjects at
recruitment. In a number of cases where antigen-specific
antibodies were detected, the frequencies of memory B cells were
below the limit of detection (Subjects 16, 17 and 29). Likewise, in
several subjects where antigen-specific antibodies were not
detected, stable frequencies of antigen-specific memory B cells
were observed (e.g. Subjects 27, 31 and 33).
Discussion
Antibodies are critical in protection against blood stage malaria
infection through numerous, diverse mechanisms [2,3]. In murine
malaria infections, B cells are required not only for the production
of protective Abs, but also for the development of T cell helper
function [26]. However, the development and persistence of B cell
memory responses following malaria infection has repeatedly been
called into question [27]. It is widely perceived that antibody titres
rapidly decline in the absence of re-infection or when individuals
leave an endemic area. It is notable that most of the studies
reporting short-lived antibody responses have been conducted at
or following the time of acute infection, and these infections were
terminated by effective antimalarial drug therapy and that these
were often observations in children [13–16,28]. It is not clear,
from these studies, whether the rapid decline of antibody
concentrations observed in children is related to removal of
antigen by chemotherapy, by consumption of antibodies and
formation of antigen-antibody complexes during parasite clear-
ance or due to limitations in the ability of the bone marrow
compartment to support differentiation and/or survival of plasma
cells [29,30]. However, the results of a recently published study in
healthy, Gambian children in which antibody titres were found to
decline more slowly both in older children and in children with
persistent asymptomatic malaria infection suggests that both
antigen persistence and immunologic maturity may be important
in determining the longevity of the serum antibody responses [15].
One explanation for these observations might be that short-lived
antibody responses are the result of induction of short-lived, but
not long-lived, plasma cells following acute malaria infection. In
murine models of malaria infection, primary P. chabaudi infection
leads to expansion of short-lived, immature B220+ splenic plasma
cells however secondary infection is accompanied by apparently
normal emergence of a larger population of fully mature (Ighi,
CD138hi, CD9+, B2202), terminally-differentiated B220- plasma
cells in the bone marrow [31], indicating that memory B cells are
efficiently induced by primary infection and are fully able to
differentiate into long-lived plasma cells on secondary exposure to
antigen. Similar studies have not been reported, to date, in
humans but we were able to take advantage of a very particular
epidemiological situation in rural Northern Thailand to examine
the natural history of the anti-malarial B cell memory response.
In our study area, both P. falciparum and P. vivax are endemic but
transmission is kept at extremely low levels by an assiduous
malaria surveillance and control programme in which all detected
infections are recorded and effectively treated [32]. We have thus
been able to recruit a cohort of individuals whose malaria infection
history over the previous 6 years are known in considerable detail
and have been able to follow these individuals for a period of 12
months to observe both long- and short-term changes in their
adaptive immune response to malaria. Furthermore, we were able
to recruit a cohort of individuals from the same community with
Table 2. Longevity of antibody and memory B cell responses to P. falciparum antigens*.
ANTIBODY
Antigen No. of subjects No. of observations Annual decline in log titre (95% CI) Antibody half-life (95% CI) p-value
PfSE 14 41 20.1264 (20.2809, 0.0282) 5.49 (2.47, ‘) 0.109
PfAMA1 8 23 20.0669 (20.2009, 0.0671) 10.36 (3.45, ‘) 0.328
PfMSP119 12 37 20.0916 (20.1959, 0.0126) 7.56 (3.54, ‘) 0.085
PfMSP1 + PfAMA1 14 60 20.0426 (20.1672, 0.082) 16.27 (4.15, ‘) 0.503
All 17 101 20.1082 (20.2153, 20.0011) 6.41 (3.22, 650.48) 0.048
B CELL MEMORY
Antigen No. of subjects No. of observations Annual decline in log titre (95% CI) Antibody half-life (95% CI) p-value
PfAMA1 13 26 0.0194 (20.3858, 0.4245) ‘ (1.8, ‘) 0.925
PfMSP119 10 19 20.0689 (20.5872, 0.4494) 10.06 (1.18, ‘) 0.794
Both 15 45 20.0928 (20.3959, 0.2102) 7.47 (1.75, ‘) 0.548
*Results from a multilevel model allowing for random patient effects.
doi:10.1371/journal.ppat.1000770.t002
B Cell Memory Responses to Plasmodium
PLoS Pathogens | www.plospathogens.org 7 February 2010 | Volume 6 | Issue 2 | e1000770
Figure 5. B cell memory responses to malaria antigens and tetanus toxoid. B cell memory responses to P. falciparum antigens (A–D), P. vivax
antigens (E and F) and tetanus toxoid (I) at the time of recruitment were determined by ELISPOT assay and are presented as the percentage of all IgG-
secreting cells that are specific for each malaria antigen. Each symbol represents the memory B cell numbers for one individual. The longevity of the
memory B cell responses specific to PfAMA-1 (G) and PfMSP-119 (H) were determined by analyzing longitudinal data with a mixed-effects model. Solid
lines represent best fit regression lines estimating the rates of decline of memory B cell numbers over time and the dashed lines represent the 95% CI.
doi:10.1371/journal.ppat.1000770.g005
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no evidence of malaria infection in the past 6 years , and a cohort
of known malaria naives from the city of Chiang Mai, where
malaria transmission was eliminated more than 30 years ago
(Suwonkerd W; The Ministry of Public Health; personal
communication). The very low levels of malaria transmission
reported in the Muang Na area [33] are confirmed by our finding
that none of the study subjects were found to be infected with
malaria parasites (detectable by blood film or PCR) at any point
during the study, none of them showed any clinical signs of
malaria infection and only one individual showed boosting of
antibody responses (and against only 1 malaria antigen) during the
study. In addition, anti-malarial antibody responses were not
correlated with age, indicating that there is likely to be little or no
effective acquired immunity to malaria in this population.
Nevertheless, some of the rural village residents with no record
or recollection of malaria infection in the past 6 years (Rural 1)
appeared to have experienced malaria infections at some time in
their lives as shown by seropositivity to malaria antigens in ELISA
and positive B cell ELISPOTs. Given the lack of evidence for
acquired protective immunity in this population, and since we
found no evidence of asymptomatic malaria infections, it is
unlikely that these individuals had experienced undiagnosed
malaria infections and thus the presence of antibodies and B cell
memory responses in this group suggests that anti-malarial
seropositivity can be maintained for many years in the absence
of reinfection.
Overall, the prevalence and magnitude of antimalarial antibody
and memory B cell responses compared favourably with the anti-
tetanus responses. Although the frequencies of tetanus-specific
memory B cells tended to be somewhat higher than the
frequencies of malaria-specific memory B cells, the prevalence of
antibodies to the P. falciparum schizont extract, PfMSP-119 and
PfAMA-1 was in fact higher than for tetanus. Thus, despite the
fact that the anti-tetanus response is likely induced by a very potent
vaccine and boosted by environmental exposure or revaccination
(which is routinely given during pregnancy), humoral immune
responses to tetanus do not appear to be particularly more robust
than those induced by infrequent natural exposure to malaria.
Moreover, frequencies of malaria-specific memory B cells in Thai
adults were similar to frequencies of diphtheria-specific memory B
cells in UK adults (J. Palomero-Gorrindo and J. Hafalla;
unpublished data). Therefore, frequencies of malaria-specific
memory B cells seem to be of the same order of magnitude as
responses to commonly used vaccine antigens [34,35]. Of note,
Buisman et al [35] also found rather higher frequencies of memory
B cells to tetanus toxoid than to other antigens.
As the time since last detected malaria infection was known for
the Rural 2 group we were able to obtain estimates of the rate of
Figure 6. Correlation between ELISA and ELISPOT responses for each antigen. For malaria antigens, data are shown for Rural 2 subjects: 33
tested against P. falciparum antigens (A–D) and 26 tested against P. vivax antigens (E and F). For TT (G), data are shown for all subjects (City naive,
Rural 1 and Rural 2) whose PBMC were available (n = 67). The number (and percentages) of subjects who were double positive (top left), ELISA
positive but ELISPOT negative (bottom left), ELISA negative but ELISPOT positive (top right), or double negative (bottom right) are shown.
doi:10.1371/journal.ppat.1000770.g006
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Table 3. Patterns of antibody and memory B cell responses to malaria antigens and tetanus toxoid in 46 Rural 2 subjects at
recruitment.
Subject PfSE[a] P.falciparum antigens P.vivax antigens Tetanus toxoid
PfAMA1 PfMSP119 PfMSP2 PfCSP PvAMA1 PvMSP119
ELISA ELISA[b] ELISPOT[c] ELISA ELISPOT ELISA ELISPOT ELISA ELISPOT ELISA ELISPOT ELISA ELISPOT ELISA ELISPOT
Tested against both P.falciparum and P. vivax antigens
1 x x x x x x
2 x x x x x x x x
3 x x x
4 x
5 x
6 x x x x x
7 x
8 x
9
10 x x x
11 x x x
12 x x
13 x x x x x
14 x x x x x
15 x x
16 x x x
17 x
18 x x x x x
19 x
20 x x x x x x x x x
21 x x
22 x x x x x x x x x
ELISPOT tested against P. falciparum antigens only
23 x x x x x x x N/D N/D x
24 x x N/D N/D x
25 N/D N/D
26 x x N/D N/D x
27 x x x x N/D N/D x x
28 x x x N/D N/D x
29 x x N/D N/D
30 x x x N/D N/D
31 x x x x N/D N/D x
32 x x x N/D N/D
33 x x x x x x N/D N/D
34 x x N/D N/D x x
35 N/D N/D
ELISPOT tested against P. vivax antigens only
36 x N/D N/D x N/D N/D
37 N/D N/D N/D N/D x x
38 x N/D x N/D N/D N/D x
39 x x N/D x N/D N/D N/D x x x
Tested for antibodies only
40 N/D N/D N/D N/D N/D N/D N/D
41 x x N/D x N/D x N/D x N/D x N/D x N/D x N/D
42 N/D x N/D N/D N/D N/D N/D N/D
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decline of both serum antibodies and circulating memory B cells.
Importantly, and in marked contrast to previously published data
from African children [14], there was no evidence of any
significant decline in either antibody titres or memory B cell
responses to PfSE, PfAMA-1 or PfMSP-119 over periods of more
than 5 years since the last known malaria infection. One reason for
this discrepancy may be that previous studies have characterised
the decay of the antibody response in the first few days or weeks
after resolution of an acute malaria infection [14,15] which is likely
to capture the initial very rapid decay in antibody titre associated
with contraction of the pool of short-lived plasma cells whereas in
this study, where the most recent malaria infection occurred many
months or years ago, we are capturing the long term ‘‘mainte-
nance’’ phase of the antibody response [36].
Our best estimates of the half-life of this maintenance phase of
antibody responses to malaria antigens ranged from ,5 to ,16
years, putting them in the same range as the half-lives recently
estimated for nonreplicating antigens such as tetanus or diptheria
toxoids [37]. However, the 95% confidence intervals for the half-
lives of these responses all included infinity, suggesting that
antibody responses to malaria may in fact be much more stable
than those to nonreplicating antigens and may be maintained in a
manner that is more similar to that of antiviral responses [37].
Similar estimates were obtained for the half lives of malaria-
specific memory B cell responses – indicating that the circulating
memory B cell pool is extremely stable - which is consistent with
data from the P. chabaudi mouse model that malaria infection
induces long-lived antibody responses as well as memory B cells
[31]. However, whilst these analyses are consistent with a long half
life for antimalarial antibody and memory cell responses, given the
very wide confidence intervals around the our estimates, data from
a larger cohort of study subjects is required to obtain definitive half
lives for these responses.
However, it is important to note that 11 subjects (24%) who
were known to have been infected with malaria had no detectable
circulating memory B cells and/or antibodies and less than 50% of
subjects tested had either antibodies or circulating memory B cells
to PfMSP-2, PfCSP, PvAMA-1 or PvMSP-119. Given that
everyone in the study had experienced their most recent malaria
infection at least 4 months before recruitment and that the
genotypes of their infecting parasites are unknown, we cannot tell
whether these seronegative individuals had completely failed to
make a humoral response to malaria, whether they had made
antibodies to polymorphic epitopes that did not cross-react with
the antigens used in our assays or whether they had developed
only very short-lived responses. In a previous study, in a higher
malaria transmission area, very short-lived antibody responses to
malaria were particularly associated with younger individuals who
(presumably) had had the fewest number of malaria infections [15]
suggesting that the long-lived responses seen in many of our study
subjects may develop only after they have experienced a number
of malaria infections. Nevertheless, given the very low levels of
malaria transmission in our study area, the number of infections
required to develop long-live antibody responses is likely to be
quite small.
Since the pharmacological half-life of a human IgG molecule is
around 21 days [38], long term maintenance of IgG titres indicates
either ongoing secretion of antibodies from plasma cells or
memory B cell differentiation in response to inflammatory stimuli;
there is still no clear consensus on whether persisting specific
antigen is required for this process [39] or not [40,41]. During
inflammation, IFN-c induces plasmablasts to express the chemo-
kine receptor CXCR3, promoting their migration into inflamed
tissues [42] and thereby maximising antibody production at sites of
infection. Resolution of inflammation leads to loss of survival
signals, and these short-lived plasma cells die in situ. However, in
the absence of prolonged antigenic stimulation, plasmablasts
express another chemokine receptor CXCR4 allowing them to
migrate to the bone marrow [43]. It is possible, therefore, that
short term fluctuations in serum antibody concentrations may
occur in response to infection with memory B cells being
stimulated to differentiate into short-lived plasma cells, secrete
immunoglobulins and then die. However, in the circumstances of
lack of frequent re-exposure to malaria infection (such as in this
study), a larger proportion of plasmablasts may differentiate into
long-lived plasma cells which maintain the level of antibodies over
time. Such a scenario does, of course, beg the question as what
would happen to long-lived plasma cells and memory B cells under
conditions of repeated or persistent malaria infection.
Immediately after malaria immunisation in humans the
frequency of antigen-specific memory B cells is positively
correlated with antibody titres [44], suggesting (not surprisingly)
that induction of antibody secreting cells and memory B cells is
linked. However, the lack of correlation that we observed between
antibody titres and memory B cell responses months or years after
exposure to malaria antigens confirms recent findings for anti-viral
responses [37] and is consistent with accumulating experimental
data from animals [45,46] and data from therapeutic B cell
depletion in humans [47,48] showing that depletion of circulating
memory B cells does not affect antibody titres, at least in the short-
Subject PfSE[a] P.falciparum antigens P.vivax antigens Tetanus toxoid
PfAMA1 PfMSP119 PfMSP2 PfCSP PvAMA1 PvMSP119
ELISA ELISA[b] ELISPOT[c] ELISA ELISPOT ELISA ELISPOT ELISA ELISPOT ELISA ELISPOT ELISA ELISPOT ELISA ELISPOT
43 x x N/D x N/D N/D N/D N/D N/D N/D
44 N/D N/D N/D N/D N/D N/D N/D
45 x x N/D x N/D x N/D N/D N/D N/D N/D
46 x N/D N/D N/D N/D N/D N/D N/D
[a]x indicates positive response to each antigen.
[b]Cut-off values were determined from a mixture model.
[c]A positive response was defined if the average number of spots from triplicate wells being greater than at least two times the average number of spots from the
media negative control.
N/D =Not done.
doi:10.1371/journal.ppat.1000770.t003
Table 3. Cont.
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term. Collectively, these data indicate that although both long-
lived plasma cells and memory B cells can be stably maintained the
two populations are independently regulated and that activation of
circulating memory B cells may not be required for maintenance
of serum antibody titres.
High affinity antibodies are expected to play an important role
in the humoral immune response. The avidity indices of antibodies
against PfAMA-1 and PfMSP-119 did not change during the 12
months of study; this is not surprising since there was no evidence
of reinfection of any of the subjects during the follow-up period
which might have driven further avidity maturation. However the
avidity of anti-PfMSP-119 antibodies was significantly higher
among Rural 2 subjects than among Rural 1 individuals,
supporting the notion that the Rural 2 population had had more
frequent exposure to malaria parasites than the Rural 1 group.
In summary, we conclude that B cell memory responses to
malaria are effectively induced and maintained – in a significant
proportion of individuals - in areas of low malaria transmission.
(This is, of course, an entirely separate issue from whether these
particular antibodies confer protective immunity to malaria; whilst
there is strong evidence to suggest that malaria-immune
individuals have very effective antimalarial antibody responses
[49] the antigenic targets of protective antibodies are still very
poorly defined. Whilst it is possible that the subjects in this study
with long-lived humoral responses to malaria antigens might be
protected from reinfection, this issue was not directly addressed in
this study). Although it remains possible that persistent and
repeated malaria infections in areas of very high endemicity may
eventually lead to B cell anergy or clonal exhaustion [50], the fact
that individuals in these areas develop high titres of antimalarial
antibodies and become resistant to high density malaria infections
and clinical symptoms argues against this as a major impediment
to the development of effective immune responses. Finally, our
results are highly encouraging for vaccine developers since they
imply that – once induced – anti-malarial immune responses are
likely to be long-lived even in the absence of frequent boosting.
Materials and Methods
Study area and subjects
Study subjects were either long-term adult residents of Muang Na,
a village in a low malaria transmission area in the Chiang Dao region
of northern Thailand, near the border with Myanmar, or were
permanent adult residents of the city of Chiang Mai where malaria
transmission does not occur. Ethical approval for the study was
obtained from the Research Institute for Health Sciences, ChiangMai
University, from the Ministry of Public Health, Thailand and from
the London School of Hygiene and Tropical Medicine, UK. Written
informed consent was obtained prior to enrolment in the study.
Subjects were interviewed to ascertain their previous malaria
exposure. Residents of Chiang Mai were selected on the basis that
they had not travelled to, or lived in, malaria endemic areas. In
Muang Na, dates and species (P. falciparum, P. vivax or both) of
malaria infections were confirmed from the records of the Office of
Vector Borne Disease Control in the Department of Communi-
cable Diseases Control at the Ministry of Public Health, which
maintains detailed records of all malaria cases detected by active
or passive case detection and during periodic population surveys as
described in detail elsewhere [51].
Venous blood was collected in acid citrate dextrose on the day
of recruitment, and again 3 months later for City naı¨ve subjects
and 3, 6 and 12 months after recruitment for rural subjects.
Giemsa-stained blood films were examined for the presence of
malaria parasites. Blood samples from each subject were checked
for subpatent malaria parasitaemia by PCR. DNA was isolated
using FlexiGene DNA extraction kits (QiagenH) according to the
manufacturer’s protocol and subjected to nested PCR for P.
falciparum and P. vivax as described previously [52].
As HIV infection may have an effect on immunological
parameters, all subjects were tested for HIV infection (presence
of anti-HIV antibodies by gel particle agglutination assay) at the
time of recruitment and at the end of the study (3 months after
recruitment for city subjects and 12 months after recruitment for
other groups); subjects received pre- and post-test counselling from
trained HIV counsellors and HIV-infected individuals were given
access to the National Antiretroviral Programme. Data from HIV-
infected subjects were excluded from the analysis.
Antigens
P. falciparum circumsporozoite protein (PfCSP) [(NANP)4] and P.
falciparum merozoite surface protein-2 (PfMSP-2) were a gift from
J.E. Tongren (Centre for Disease Control and Prevention, Atlanta,
GA, USA). The 19kDa fragments of P. falciparum and P. vivaxMSP-1
(PfMSP-119 and PvMSP-119) were gifts from A. Holder (National
Institute of Medical Research, London, UK) and the proteins were
expressed as described [53]. P. falciparum apical membrane antigen-
1 (PfAMA-1) was a gift from R.F. Anders (LaTrobe University,
Victoria, Australia); the equivalent P.vivax antigen (PvAMA-1) was a
gift from B. Farber and A. Thomas (Biomedical Primate Research
Centre, Rijswik, Netherlands). P. vivax duffy binding protein
(PvDBP) was a gift from L.H. Carvalho Centro de Pesquisas Rene´
Rachou, Fundac¸a˜o Oswaldo Cruz, Belo Horizonte, MG, Brazil).
Since Thai populations are routinely vaccinated with tetanus toxoid
(TT), antibody responses to TT were included as a positive control.
TT was obtained from the National Institute of Biological
Standards and Control (Health Protection Agency, Hertfordshire,
UK). Keyhole limpet haemocyanin (KLH) was from Thermos
Fisher Scientific (Northumberland, UK).
Continuous cultures of P. falciparum (3D7 strain were maintained
in the laboratory [54] and were periodically shown to be free from
Mycoplasma contamination by polymerase chain reaction (PCR)
(VenorH GeM, Minerva Biolabs). Mature schizonts were obtained
by gradient centrifugation over 60% Percoll (Amersham Biosci-
ences), adjusted to a concentration 16108 schizont-infected red
blood cells (iRBC)/ml and exposed to three freeze/thaw cycles to
obtain P. falciparum schizont extract (PfSE).
Enzyme-linked immunosorbent assay (ELISA)
Plasma antibody levels were detected by indirect ELISA, as
described [55]. Briefly, Immulon 4HB (Dynatech) or Maxisorb
(Nunc) plates were coated with antigen (at a concentration
equivalent to 105 iRBC/ml for PfSE, 0.5 mg/ml for Plasmodium-
derived antigens and TT) in bicarbonate buffer (pH 9.6) overnight
at 4uC. Plates were blocked with PBS containing 1% non-fat milk
powder. Diluted plasma samples (1:200 for PfCSP, 1:1000 for
PfSE, PfMSP-119, PfMSP-2, PvMSP-119 and PvDBP; 1:2000 for
PfAMA-1, PvAMA-1 and TT) were incubated in dubplicate.
Plates were subsequently developed with anti-human IgG
horseradish peroxidase conjugate (Caltag Laboratories, Invitro-
gen, Paisley, UK) followed by o-phenylenediamine substrate
(Sigma). The enzyme reaction was terminated with sulphuric acid
(2N) and absorbance was then read at 492 nm on a Spectra MR
plate reader (Dynex Technology).
Antibody levels were determined by comparison to a standard
curve (derived by serial dilution of a pool of hyperimmune plasma
collected in The Gambia, which was given an arbitrary value of
1,000 units/ml of anti-PfSE Abs) on each plate, as described
previously [12].
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Preparation of peripheral blood mononuclear cells
(PBMCs)
PBMCs were separated from citrated blood by gradient
centrifugation over Ficoll-Hypaque (Amersham Biosciences). Con-
taminating erythrocytes were removed by incubating with lysis
buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA) at
RT for 5 minutes. The cells were washed twice with RPMI,
resuspended in 10% human AB serum/RPMI (R10 culture
medium), counted, adjusted to the required concentration and
cryopreserved in 10% dimethylsulfoxide (DMSO)/foetal calf serum.
Stimulation of cryopreserved PBMC for B cell ELISPOT
assay
Cryopreserved PBMCs were quick thawed in a 37uC water
bath. The cells were washed twice with warm RPMI, resuspended
in R10 culture medium and added at a concentration of 16106
cells/ml to a 24 well culture plate. The cells were stimulated with
medium alone or with a mixture of Phytolacca americana pokeweed
mitogen (1/100,000 dilution; a gift from M. Causland and S.
Crotty, La Jolla Institute of Allergy and Immunology, CA, USA),
6 mg/ml CpG 2006 (Qiagen/Operon), and 1/10,000 dilution of
Staphylococcus Aureus Cowan (SAC) (Sigma), as previously
described [25]. The culture plates were incubated in 5% CO2 at
37uC for 5 days.
B cell ELISPOT assay
B cell ELISPOT assays were performed as described previously
[25]. Briefly, ELISPOT plates (Millipore) were coated with donkey
anti-human IgG (H+L) (Jackson ImmunoResearch), or with 1 mg/
ml recombinant malaria proteins overnight at 4uC. After washing
once with PBS-T and three times with PBS, 200 ml of 1% bovine
serum albumin in RPMI were added to each well and incubated
for 2 hours at 37uC, 5% CO2. Cultured PBMCs were recovered
from the 24 well culture plates, washed, transferred directly to
antigen-coated ELISPOT plates and incubated for 6 hours at
37uC, 5% CO2. After 4 washes with PBS and 4 washes with PBS-
T, 100 ml of Biotin-SP-conjugated donkey anti-human IgG
(Jackson Immunoresearch) were added to each well and the plates
were incubated overnight at 4uC. The plates were washed, 100 ml
of alkaline phosphatase-streptavidin (Vector Laboratories) was
added and incubated for one hour at room temperature. After
three washes with PBS-T and three washes with PBS, 100 ml of 5-
bromo-4-chloro-3-indolyl phosphate/ nitro blue tetrazolium -
alkaline phosphatase substrate solution (Vector Laboratories) were
added to each well and the reaction was allowed to proceed for
8 minutes before being stopped with distilled water. In vitro
restimulated PBMCs incubated overnight with an irrelevant
protein, KLH, as well as PBMCs cultured without stimulation
and then incubated overnight with malaria antigens were used as
negative controls. Since no malaria-specific spots were detected in
city naı¨ve individuals, this group was not be used to set a cut-off for
positivity. Rather, a positive ELISPOT response was defined when
spots were observed in 2 or more replicate wells and where the
total number of spots in the antigen-coated wells was at least twice
the number observed in the negative control wells.
Avidity assay
An enzyme immunoassay for determination of antibodies
against malaria antigens was carried out as described above.
Following the incubation step of sera with antigens, one duplicate
set of sera was treated with 4.0 M guanidine dissociating solution
(Guanidine Hydrochloride, Sigma) for 10 minutes prior to
washing with PBS-T. Avidity indices were calculated as the ratio
of the OD of guanidine -treated wells to the OD of the untreated
wells.
Statistical analysis
To determine whether an individual was seropositive for a
particular antigen (PfSE, Pf- or Pv-derived antigens, or TT), cut-
offs for positive antibody titres were calculated using a mixture
model, which assumes that untransformed titres for seropositive
and seronegative samples each follow a normal Gaussian
distribution [56,57]. Mann Whitney U test was used to analyse
differences in the levels of antibodies or memory B cells among
groups (GraphPad Prism software). Fischer’s exact test was used to
analyse differences in the proportion of positive individuals
between Rural 1 and Rural 2 groups, as well as differences in
the proportion of seropositives at recruitment compared to 12
months later. Decay rates for antibody titres and memory B cell
frequencies were calculated using logarithmically transformed data
from subjects who were seropositive or memory B cell positive,
respectively, at recruitment. The effect of time since malaria
infection was analysed using a log-linear mixed-effects regression
model incorporating Gaussian random intercepts. This resulted in
an estimate of the decay rate of antibody titres or memory B cell
frequencies, assuming a single-exponential decay model. Half-lives
were calculated from the estimated decay rate and the boundaries
at 95% confidence interval obtained from the mixed-effects model.
Where the decay rate is a positive value, the calculated half-life is
reported as infinity. All analyses were undertaken using Stata
(version 10, Statacorp LP).
Supporting Information
Figure S1 Antibody responses against PfSE in P. falciparum
(square) and P. vivax (diamond) exposed subjects. Each symbol
represents the antibody titre of one individual. Dotted lines show
cut-off values calculated from a mixture model as described in
materials and methods. Solid lines show the median antibody titres
in each group.
Found at: doi:10.1371/journal.ppat.1000770.s001 (0.03 MB
DOC)
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